secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001193125-26-152039
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines' daraxonrasib Phase 3 trial meets OS endpoint: 13.2 vs 6.7 months, HR 0.40
--------------------------------------------------------------------------------

- Phase 3 RASolute 302 trial: median OS 13.2 mo vs 6.7 mo for chemo (HR 0.40, p<0.0001); PFS also statistically significant.
- Daraxonrasib generally well tolerated with manageable safety profile; no new safety signals.
- Trial results considered final from first interim analysis; company to submit to FDA and other global regulators.
- Data to support future NDA via a Commissioner’s National Priority Voucher.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312526152039/0001193125-26-152039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312526152039/d69348d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-152039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer